{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:00:53Z","timestamp":1792533653517,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":45,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.rpth.2025.102865","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T03:02:50Z","timestamp":1745290970000},"page":"102865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3909-0570","authenticated-orcid":false,"given":"C\u0103t\u0103lina","family":"Codreanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-6491","authenticated-orcid":false,"given":"Tessa","family":"Elling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1492-7937","authenticated-orcid":false,"given":"Nic J.G. M.","family":"Veeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3976-8001","authenticated-orcid":false,"given":"Wilfried W.H.","family":"Roeloffzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9447-0465","authenticated-orcid":false,"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.102865_bib1","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102865_bib2","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00432-021-03693-5","article-title":"Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study","volume":"148","author":"Leclerc","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.rpth.2025.102865_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-0031-1273085","article-title":"Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis","volume":"37","author":"Zamagni","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2025.102865_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2009-12-257519","article-title":"High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study","volume":"116","author":"Libourel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102865_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00513-4","article-title":"Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy","volume":"11","author":"Chakraborty","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.rpth.2025.102865_bib6","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102865_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.clml.2014.05.003","article-title":"Thrombosis and hemostatic abnormalities in hematological malignancies","volume":"14","author":"Colombo","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.rpth.2025.102865_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/healthcare4010016","article-title":"Incidence and risk factors of thromboembolism with multiple myeloma in the presence of death as a competing risk: an empirical comparison of statistical methodologies","volume":"4","author":"Brown","year":"2016","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.rpth.2025.102865_bib9","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1080\/10428194.2023.2247513","article-title":"Thrombosis in multiple myeloma: mechanisms, risk assessment and management","volume":"64","author":"Jarchowsky","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.rpth.2025.102865_bib10","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.3390\/cancers14246216","article-title":"Approach to contemporary risk assessment, prevention and management of thrombotic complications in multiple myeloma","volume":"14","author":"Fotiou","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.rpth.2025.102865_bib11","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE Score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2025.102865_bib12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.rpth.2025.102865_bib13","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood.2022015727","article-title":"Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score","volume":"140","author":"Chakraborty","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102865_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines insights: multiple myeloma, version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.rpth.2025.102865_bib15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2025.102865_bib16","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network. European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2025.102865_bib17","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.102865_bib18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102865_bib19","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/cncr.32682","article-title":"Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis","volume":"126","author":"Chakraborty","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.rpth.2025.102865_bib20","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.102865_bib21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMe1816060","article-title":"Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer","volume":"380","author":"Agnelli","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.102865_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.102865_bib23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjh.15392","article-title":"Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens","volume":"185","author":"Storrar","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.102865_bib24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ajh.25459","article-title":"Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study","volume":"94","author":"Pegourie","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2025.102865_bib25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjh.16653","article-title":"Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents","volume":"190","author":"Cornell","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.102865_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.17772","article-title":"Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis","volume":"196","author":"Piedra","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.102865_bib27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/1078155221995885","article-title":"Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system","volume":"28","author":"Parnes","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.rpth.2025.102865_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2022.03.001","article-title":"Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: a prospective cohort study","volume":"213","author":"Sayar","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.102865_bib29","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1007\/s10238-023-01080-7","article-title":"Thrombosis events in Chinese patients with newly diagnosed multiple myeloma","volume":"23","author":"Li","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.rpth.2025.102865_bib30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.19017","article-title":"Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: a systematic review and updated meta-analysis","volume":"203","author":"Costa","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.102865_bib31","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2025.102865_bib32","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102865_bib33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.rpth.2025.102865_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.rpth.2025.102865_bib36","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2025.102865_bib37","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2025.102865_bib38","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102865_bib39","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102865_bib40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12885-023-10787-5","article-title":"Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany","volume":"23","author":"Eisfeld","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.rpth.2025.102865_bib41","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/cancers12010191","article-title":"Multiple myeloma and thrombosis: prophylaxis and risk prediction tools","volume":"12","author":"Fotiou","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.rpth.2025.102865_bib42","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2019-128095","article-title":"Patient preferences regarding anticoagulation therapy in patients with cancer having a VTE event\u2014a discrete choice experiment in the Cosimo Study","volume":"134","author":"Picker","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102865_bib43","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/bloodadvances.2019000462","article-title":"Patient values and preferences regarding VTE disease: a systematic review to inform American Society of Hematology guidelines","volume":"4","author":"Etxeandia\u2013Ikobaltzeta","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.102865_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.675969","article-title":"Patient characteristics and preferences regarding anticoagulant treatment in venous thromboembolic disease","volume":"8","author":"Lan\u00e9elle","year":"2021","journal-title":"Front Cardiovasc Med"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S247503792500189X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S247503792500189X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:18:54Z","timestamp":1761841134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S247503792500189X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S247503792500189X"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102865","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102865"}}